SoCal TBA March 2022 online event-From Academia to Industry: Opportunities and Challenges as a Neuroscientist
Speaker: 黃正球 (Cheng-Chiu Joe Huang), Director and Project Lead of Neuroscience NGTx at Eli Lilly
Time: Mar 26, 2022 11 AM Pacific Time (US and Canada)
Registration Link: https://socaltba2022marcc.eventbrite.com
SoCal TBA 本次榮幸邀請到在Eli Lilly Neuroscience NGTx 擔任Director and Project Lead的黃正球博士(Cheng-Chiu Joe Huang) 主講。黃博士擁有豐富的學術研究經歷，其成果曾刊登於著名期刊(Nature Medicine, Neuron等)，以及具有開發神經退化性疾病和疼痛管理藥物的經驗。本次活動中他將分享自身在產學界的歷程，也會與我們一同探討神經科學在生醫製藥的展望。你不會想錯過:
Dr. Cheng-Chiu (Joe) Huang, a Ph.D. in Developmental Biology and Neuroscience, has extensive experience working on preclinical animal models, in vivo pharmacology, early clinical development, and project management in both academia and the biotech industry.
His track record of innovations in genetic medicine (RNA and Gene Therapy) for neurological and immunological diseases includes not only his publications about genetic and viral tools development for sensory disorders, but also multiple discovery programs in neuro-immune interactions, autonomic hyperreflexia, and immuno-oncology. After transitioning into industry, he has also managed a pipeline project in postsurgical pain management toward Investigational New Drug Application (IND) application and successful clinical development.
Dr. Huang has also established his management and leadership roles across different stages in his career. Supervising junior scientists in academia, he served as the director of cross-functional teams, with external partners and CROs on harnessing novel therapeutic modalities to tackle chronic pain and neurodegenerative diseases, and on building IP moat around the assets. He has been a senior scientific prospector of more than 30 due diligence activities in scouting assets and M&A targets ranging from preclinical to human phase 2 stages, and is currently the Director and Project Lead of Neuroscience NGTx at Eli Lilly.